NovImmune SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NovImmune SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7597
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and kappa-lambda bispecific antibody platform. Its pipeline products include Emapalumab, a human anti-IFNy monoclonal antibody used for the treatment of Hemophagocytic Lymphohistiocytosis; NI-0101, a toll-like receptor 4 monoclonal antibody; NI-1201, a monoclonal antibody intended to interact with IL-6 receptor to suppress Interleukin-6 (IL-6) driven inflammation; and others. The company has partnership with various pharmaceutical companies to develop monoclonal and bispecific antibodies. It has a presence in Geneva and Basel, Switzerland. NovImmune is headquartered in Geneva, Switzerland.

NovImmune SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NovImmune SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
Partnerships 13
TG Therapeutics and Novimmune Enter into Agreement 13
Novimmune and LegoChem Biosciences Enter into Research Agreement 14
Novimmune Enters into Research Agreement with Baxalta 15
Licensing Agreements 16
Swedish Orphan Biovitrum to Enter into Licensing Agreement with Novimmune 16
Shire Enters into Licensing Agreement with Novimmune 17
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 18
Genentech Enters into Licensing Agreement with Novimmune 19
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 20
NovImmune SA – Key Competitors 21
NovImmune SA – Key Employees 22
NovImmune SA – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Product News 24
03/27/2017: Novimmune opens a Branch Office in Basel 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
NovImmune SA, Pharmaceuticals & Healthcare, Key Facts 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NovImmune SA, Deals By Therapy Area, 2012 to YTD 2018 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
TG Therapeutics and Novimmune Enter into Agreement 13
Novimmune and LegoChem Biosciences Enter into Research Agreement 14
Novimmune Enters into Research Agreement with Baxalta 15
Swedish Orphan Biovitrum to Enter into Licensing Agreement with Novimmune 16
Shire Enters into Licensing Agreement with Novimmune 17
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 18
Genentech Enters into Licensing Agreement with Novimmune 19
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 20
NovImmune SA, Key Competitors 21
NovImmune SA, Key Employees 22
NovImmune SA, Other Locations 23

List of Figures
NovImmune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NovImmune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[NovImmune SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hovnanian Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Maxeda B.V.:戦略・SWOT・企業財務分析
    Maxeda B.V. - Strategy, SWOT and Corporate Finance Report Summary Maxeda B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • OPG Power Ventures Plc (OPG):企業の財務・戦略的SWOT分析
    OPG Power Ventures Plc (OPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hadera Paper Ltd.:企業の戦略・SWOT・財務情報
    Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PT Pertamina (Persero):企業の戦略的SWOT分析
    PT Pertamina (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Baker & McKenzie LLP:企業の戦略的SWOT分析
    Baker & McKenzie LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • Compagnie Financiere Richemont SA (CFR):企業の財務・戦略的SWOT分析
    Compagnie Financiere Richemont SA (CFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Cyalume Technologies Holdings, Inc.:企業の戦略・SWOT・財務情報
    Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Bank Rossiya:企業の戦略・SWOT・財務分析
    Bank Rossiya - Strategy, SWOT and Corporate Finance Report Summary Bank Rossiya - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Theravectys SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Theravectys SA (TheraVectys) is a clinical development biotech company that develops new generation therapeutic vaccines and immunotherapies. The company develops viral vectors vaccines to support body and prepare against future infections by pre-exposing immune system to partial, dead, inac …
  • Plenus Company Limited:企業の戦略・SWOT・財務情報
    Plenus Company Limited - Strategy, SWOT and Corporate Finance Report Summary Plenus Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Omega Pharma NV:企業の戦略・SWOT・財務情報
    Omega Pharma NV - Strategy, SWOT and Corporate Finance Report Summary Omega Pharma NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • British Columbia Cancer Agency:医療機器:M&Aディール及び事業提携情報
    Summary British Columbia Cancer Agency (BC Cancer Agency), a subsidiary of Provincial Health Services Authority is a healthcare service center that provides comprehensive cancer control program. The center offers services such as diagnostic and therapy planning, radiation therapy, patient assessment …
  • Travelzoo Inc.:企業の戦略・SWOT・財務情報
    Travelzoo Inc. - Strategy, SWOT and Corporate Finance Report Summary Travelzoo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Medigen Biotechnology Corp (3176)-製薬・医療分野:企業M&A・提携分析
    Summary Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses at developing new therapeutics, principally in the area of cancer and liver diseases. The company’s pro …
  • Risco Energy Investments Pte Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Risco Energy Investments Pte Ltd (Risco Energy Investments) is an energy investment company that acquires, operates, runs, deals, manages, funds and commercialize oil and gas assets. The company undertakes hydrocarbon exploration, production, development, power generation and gas commerciali …
  • Classic Cosmetics Inc:企業の戦略・SWOT・財務情報
    Classic Cosmetics Inc - Strategy, SWOT and Corporate Finance Report Summary Classic Cosmetics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bonavista Energy Corp (BNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Korean Air Lines Co Ltd
    Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆